Company / Share Buybacks
Gilead Sciences Share Buybacks History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Share Buybacks
$1.9B
FY2025
5-year range
$546.0M / $1.9B
FY2021-FY2025
Trend
+67.1%
vs FY2024
Sector context
#6 of 48
Health Care
What the data says
Gilead Sciences's share buybacks of $1.9B is higher than 88% of companies in the Health Care sector (FY2025). Share Buybacks has fluctuated over the past 10 years, ranging from $546M in FY2023 to $11.0B in FY2018.
Based on SEC 10-K filings.
$1.9B in FY2025 with a 5-year CAGR of +4.0%. Top quartile in the Health Care sector.
Improved from $546M to $1.9B over the past 2 years.
Health Care sector context is included.
Share Buybacks over time
Growth rates
- 3-Year CAGR
- +6.7%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 48This company $1.9B Sector average $611.9M
▼
+214.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.0%, indicating consistent growth.
- In FY2025, share buybacks increased 67.1% year-over-year.
- Ranks #6 out of 48 companies in the Health Care sector.
- Peak share buybacks was recorded in FY2018.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Share BuybacksValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9B | +67.1% |
| FY2024 | $1.1B | +110.6% |
| FY2023 | $546.0M | -65.5% |
| FY2022 | $1.6B | -9.5% |
| FY2021 | $1.7B | +10.5% |
| FY2020 | $1.6B | +65.9% |
| FY2019 | $954.0M | -91.3% |
| FY2018 | $11.0B | +10.0% |
| FY2017 | $10.0B | +87.0% |
| FY2016 | $5.3B | -46.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026